Risk factors associated with pulmonary exacerbations in pediatric patients with cystic fibrosis

被引:1
|
作者
Lubovich, Silvina [1 ]
Zaragoza, Silvina [1 ]
Rodriguez, Viviana [1 ]
Buendia, Jefferson [2 ]
Camargo Vargas, Bethy [1 ]
Alchundia Moreira, Jessica [1 ]
Galanternik, Laura [3 ]
Ratto, Patricia [4 ]
Teper, Alejandro [1 ]
机构
[1] Hosp Ninos Dr Ricardo Gutierrez, Unit 3, Resp Ctr, Buenos Aires, DF, Argentina
[2] Hosp Italiano Buenos Aires, Div Pediat Pulmonol, Buenos Aires, DF, Argentina
[3] Hosp Ninos Dr Ricardo Gutierrez, Dept Microbiol, Buenos Aires, DF, Argentina
[4] Hosp Ninos Dr Ricardo Gutierrez, Dept Kinesiol, Buenos Aires, DF, Argentina
来源
ARCHIVOS ARGENTINOS DE PEDIATRIA | 2019年 / 117卷 / 05期
关键词
pulmonary exacerbations; cystic fibrosis; PSEUDOMONAS-AERUGINOSA; OUTCOMES; CHILDREN; IMPACT; LIFE;
D O I
10.5546/aap.2019.eng.e466
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction. Cystic fibrosis patients develop pulmonary exacerbations (PEs) that require intravenous treatment. The objective of this study was to determine the risk factors associated with PEs and establish the percentage of patients who failed to recover their lung function. Population and methods. Observational, retrospective, cohort study. The medical records of cystic fibrosis patients seen at Hospital de Ninos Ricardo Gutierrez in 2013 were reviewed. Patients were divided into group 1, with PE (Fuchs criteria), and group 2, without PE. Age, sex, p.F508del mutation, percentage of baseline forced expiratory volume in the first second, baseline body mass index Z-score, chronic Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex colonization (Leeds criteria), percentage of cystic fibrosis-related diabetes, and recovery of baseline forced expiratory volume in the first second were recorded. Results. A total of 117 patients were included. Group 1: 50, group 2: 67 patients. PEs were associated with a lower body mass index Z-score (RR: 1.45; p = 0.002), p.F508del mutation (RR: 3.23; p = 0.05), and chronic Burkholderia cepacia complex (RR: 3.69; p = 0.002), Pseudomonas aeruginosa (RR: 1.89; p = 0.01) and methicillin-resistant Staphylococcus aureus colonization (RR: 2.32; p = 0.002). Twenty-four percent of patients failed to recover their lung function. Conclusions. The presence of the p. F508del mutation, a poor nutritional status, and chronic colonization were the risk factors for exacerbation. A fourth of patients failed to recover their lung function.
引用
收藏
页码:E466 / E471
页数:6
相关论文
共 50 条
  • [41] Patient factors associated with lung transplant referral and waitlist for patients with cystic fibrosis and pulmonary fibrosis
    Liu, Yuan
    Vela, Monica
    Rudakevych, Tanya
    Wigfield, Christopher
    Garrity, Edward
    Saunders, Milda R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (03) : 264 - 271
  • [42] Factors associated with lung function response with oral antibiotic treatment of pulmonary exacerbations in cystic fibrosis
    Blanchard, Ana C.
    Shaw, Michelle
    Ratjen, Felix
    Tullis, Elizabeth
    Daneman, Nick
    Waters, Valerie
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (05) : 880 - 883
  • [43] Pulmonary Exacerbations in Cystic Fibrosis With Negative Bacterial Cultures
    Zemanick, Edith T.
    Wagner, Brandie D.
    Harris, J. Kirk
    Wagener, Jeffery S.
    Accurso, Frank J.
    Sagel, Scott D.
    PEDIATRIC PULMONOLOGY, 2010, 45 (06) : 569 - 577
  • [44] Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations
    Waters, Valerie
    Stanojevic, Sanja
    Klingel, Michelle
    Chiang, Jackie
    Sonneveld, Nicole
    Kukkar, Richa
    Tullis, Elizabeth
    Ratjen, Felix
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (06) : 770 - 776
  • [45] Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort study
    Emiralioglu, Nagehan
    Cakir, Banu
    Sertcelik, Ahmet
    Yalcin, Ebru
    Kiper, Nural
    Sen, Velat
    Altintas, Derya Ufuk
    Serbes, Mahir
    Cokugras, Haluk
    Kilinc, Ayse Ayzit
    Baskan, Azer Kilic
    Hepkaya, Evrim
    Yazan, Hakan
    Turel, Ozden
    Kafi, Hale Molla
    Yilmaz, Asli Imran
    Unal, Gokcen
    Caglar, Tugce
    Damadoglu, Ebru
    Irmak, Ilim
    Demir, Esen
    Ozturk, Gokcen
    Bingol, Aysen
    Basaran, Erdem
    Sapan, Nihat
    Aslan, Ayse Tana
    Asfuroglu, Pelin
    Harmanci, Koray
    Kose, Mehmet
    Hangul, Melih
    Ozdemir, Ali
    Tugcu, Gokcen
    Polat, Sanem Eryilmaz
    Ozcan, Gizem
    Gayretli, Zeynep Gokce
    Keskin, Ozlem
    Bilgic, Sevgi
    Yuksel, Hasan
    Ozdogan, Sebnem
    Topal, Erdem
    Caltepe, Gonul
    Can, Demet
    Ekren, Pervin Korkmaz
    Kilic, Mehmet
    Suleyman, Ayse
    Eyuboglu, Tugba Sismanlar
    Cinel, Guzin
    Pekcan, Sevgi
    Cobanoglu, Nazan
    Cakir, Erkan
    PEDIATRIC PULMONOLOGY, 2024, 59 (11) : 2956 - 2966
  • [46] Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis
    McElvaney, Oliver J.
    Heltshe, Sonya L.
    Odem-Davis, Katherine
    West, Natalie E.
    Sanders, Don B.
    Fogarty, Barbra
    VanDevanter, Donald R.
    Flume, Patrick A.
    Goss, Christopher H.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (05) : 716 - 726
  • [47] Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations
    West, Natalie E.
    Beckett, Valeria V.
    Jain, Raksha
    Sanders, Don B.
    Nick, Jerry A.
    Heltshe, Sonya L.
    Dasenbrook, Elliott C.
    VanDevanter, Donald R.
    Solomon, George M.
    Goss, Christopher H.
    Flume, Patrick A.
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (05) : 600 - 606
  • [48] IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis
    VanDevanter, Donald R.
    Morris, Nathan J.
    Konstan, Michael W.
    JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (03) : 372 - 379
  • [49] Changes in Pediatric Health-Related Quality of Life in Cystic Fibrosis After IV Antibiotic Treatment for Pulmonary Exacerbations
    Modi, Avani C.
    Lim, Crystal S.
    Driscoll, Kimberly A.
    Piazza-Waggoner, Carrie
    Quittner, Alexandra L.
    Wooldridge, Jamie
    JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS, 2010, 17 (01) : 49 - 55
  • [50] Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations eICE Study Results
    Lechtzin, Noah
    Mayer-Hamblett, Nicole
    West, Natalie E.
    Allgood, Sarah
    Wilhelm, Ellen
    Khan, Umer
    Aitken, Moira L.
    Ramsey, Bonnie W.
    Boyle, Michael P.
    Mogayzel, Peter J., Jr.
    Gibson, Ronald L.
    Orenstein, David
    Milla, Carlos
    Clancy, John P.
    Antony, Veena
    Goss, Christopher H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 196 (09) : 1144 - 1151